Payment overview · 2025
General Payments
$685.09
27 reported records · 12 companies
Healthcare provider profile · identity verified
Alam A Khan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1316946288
Verified facts
What the public records show
CMS Open Payments records show Alam A Khan, M.D. received $685.09 in general payments during 2025 across 27 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $177.17 | 25.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.51 | 12.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.30 | 10.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.40 | 10.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.41 | 9.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.58 | 8.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.17 | 5.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.40 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.06 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.35 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.17 | 3.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.57 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $573.60 | 26 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $92.87 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $82.51 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.51 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $65.68 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.41 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.58 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 452 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
452 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 151 |
| Eliquis | Apixaban | 452 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 101 |
| Gabapentin | Gabapentin | 313 | 61 |
| Furosemide | Furosemide | 284 | 70 |
| Lisinopril | Lisinopril | 281 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 279 | 69 |
| Potassium Chloride | Potassium Chloride | 272 | 41 |
| Losartan Potassium | Losartan Potassium | 251 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 38 |
| Metformin Hcl | Metformin Hcl | 206 | 46 |
| Simvastatin | Simvastatin | 203 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 178 | 24 |
| Omeprazole | Omeprazole | 176 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 46 |
| Trazodone Hcl | Trazodone Hcl | 172 | 33 |
| Mirtazapine | Mirtazapine | 163 | 31 |
| Donepezil Hcl | Donepezil Hcl | 148 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 26 |
| Carvedilol | Carvedilol | 111 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 25 |
| Sertraline Hcl | Sertraline Hcl | 110 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 92 | 19 |
| Spironolactone | Spironolactone | 92 | 25 |
| Allopurinol | Allopurinol | 86 | 17 |
| Jardiance | Empagliflozin | 86 | 18 |
| Levetiracetam | Levetiracetam | 82 | 13 |
| Risperidone | Risperidone | 79 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 15 |
| Enoxaparin Sodium | Enoxaparin Sodium | 77 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 74 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 24 |
| Warfarin Sodium | Warfarin Sodium | 71 | suppressed |
| Humalog | Insulin Lispro | 68 | suppressed |
| Xarelto | Rivaroxaban | 66 | 14 |
| Finasteride | Finasteride | 64 | 12 |
| Glipizide | Glipizide | 62 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 61 | 11 |
| Famotidine | Famotidine | 57 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Alprazolam | Alprazolam | 53 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Olanzapine | Olanzapine | 51 | suppressed |
| Azithromycin | Azithromycin | 50 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 13 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 29 |
| Lokelma | Sodium Zirconium Cyclosilicate | 44 | suppressed |
| Xifaxan | Rifaximin | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Amantadine | Amantadine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 15 |
| Nifedipine Er | Nifedipine | 38 | 14 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Acetic Acid | Acetic Acid | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 25 |
| Enulose | Lactulose | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Baclofen | Baclofen | 26 | 12 |
| Calcium Acetate | Calcium Acetate | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Clozapine | Clozapine | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Prednisone | Prednisone | 16 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $685.09 · 27 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, KRYSTEXXA, LEQVIO, MOUNJARO, NURTEC ODT, REXULTI, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error